ReviewAnnals of hematology2024
Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.
Review in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL-2 Inhibitors.Cancer medicine · 2026Article
- Vitreoretinal lymphoma revealing Richter transformation.American journal of ophthalmology case reports · 2026Article
- Article
- Aortic dissection secondary to lymphoma: A rare surgical emergency.JTCVS open · 2026Article
- Progressive Rapid Atherosclerotic Plaque Formation and Early Stent re-Stenosis in an Untreated CLL Patient; A Case Report.Clinical case reports · 2026Article
- Article
- Article
- Existing and emerging strategies for fertility preservation in female patients with leukemia.Frontiers in endocrinology · 2026Review
- Extranodal Manifestation of Chronic Lymphocytic Leukemia: A Case of Bilateral Breast Involvement.Clinical case reports · 2025Article
- Muscle Infiltration in Chronic Lymphocytic Leukemia: A Diagnostic Challenge.Diagnostics (Basel, Switzerland) · 2025Article
- Subcutaneous Leukemia Cutis as the Initial Manifestation of CD23 Negative CLL/SLL in a Patient With Rheumatoid Arthritis on Chronic TNF-Alpha Inhibition.Case reports in hematology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a common leukemia characterized by clonal expansion of mature CD5+/CD23 + B cells in the blood, bone marrow (BM) and lymphoid tissues. CLL can undergo extramedullary and extranodal infiltration, with one study noting an incidence of only 0.3 per 100,000 people, and in 17.6% of CLL patients in another report. The most common extranodal sites of leukemic involvement are the skin and central nervous system; however, other organs, including liver, lungs, kidney, gastrointestinal tract, bone, prostate and heart, are occasionally involved. The prognostic significance of extra-medullary CLL is still under debate, but the prognosis in such patients seems to be better in the era of novel targeted drugs. Following a diagnosis of extranodal CLL, survival appears to depend on the site of infiltration. This review presents an overview of CLL in patients with extramedullary and extranodal leukemic lesions, focusing on its epidemiology, pathogenesis, prognosis, clinical characteristics and treatment results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.